Open Market Insiders Trades
This list includes insiders general transaction with codes filed in Form 4 from SEC:
- P - Open market or private purchase of non-derivative or derivative security
- S - Open market or private sale of non-derivative or derivative security
- V - Transaction voluntarily reported earlier than required
| Ticker | Insider | Transaction Type | Ownership Type | Shares Traded | Value / Price | Filing Date |
|---|---|---|---|---|---|---|
|
APLS
|
Cedric Francois
Chief Executive Officer |
SELL
Open market or private sale
|
Direct | 6,007 Reduced 1.95% |
$179,969
$29.96 p/Share
|
Jan 17
2025 |
|
EQIX
|
Charles J Meyers
Director |
SELL
Open market or private sale
|
Direct | 4,241 Reduced 27.84% |
$3,902,313
$920.14 p/Share
|
Jan 17
2025 |
|
APLS
|
Caroline Baumal
Chief Medical Officer |
SELL
Open market or private sale
|
Direct | 1,853 Reduced 3.34% |
$55,515
$29.96 p/Share
|
Jan 17
2025 |
|
APLS
|
James George Chopas
VP/Chief Accounting Officer |
SELL
Open market or private sale
|
Direct | 715 Reduced 1.91% |
$21,421
$29.96 p/Share
|
Jan 17
2025 |
|
APLS
|
Mark Jeffrey De Long
Chief Business & Strat Officer |
SELL
Open market or private sale
|
Direct | 1,235 Reduced 2.1% |
$37,000
$29.96 p/Share
|
Jan 17
2025 |
|
PLAB
|
Kang Jyh Lee
CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct | 10,000 Reduced 1.75% |
$244,700
$24.47 p/Share
|
Jan 17
2025 |
|
QK
|
Hrt Financial LP
> 10% Shareholder |
SELL
Open market or private purchase
|
Direct | 78,275 Reduced 100.0% |
$93,930
$1.2 p/Share
|
Jan 17
2025 |
|
AIR
|
John Mc Clain Holmes Iii
Chairman, President & CEO |
SELL
Open market or private sale
|
Direct | 5,000 Reduced 1.44% |
$354,050
$70.81 p/Share
|
Jan 17
2025 |
|
RCG
|
Murray Stahl
President and CEO |
BUY
Open market or private purchase
|
Indirect | 870 Added 0.0% |
$2,340
$2.69 p/Share
|
Jan 17
2025 |
|
RCG
|
Murray Stahl
President and CEO |
BUY
Open market or private purchase
|
Direct | 328 Added 0.62% |
$882
$2.69 p/Share
|
Jan 17
2025 |
|
BKE
|
Dennis H Nelson
President & CEO |
SELL
Open market or private sale
|
Indirect | 100 Reduced 0.0% |
$4,803
$48.03 p/Share
|
Jan 17
2025 |
|
MMD
|
David Dowden |
BUY
Open market or private purchase
|
Direct | 3,300 Added 50.0% |
$49,236
$14.92 p/Share
|
Jan 17
2025 |
|
NXJ
|
Saba Capital Management, L.P.
> 10% Shareholder |
SELL
Open market or private sale
|
Indirect | 45,524 Reduced 0.0% |
$551,750
$12.12 p/Share
|
Jan 17
2025 |
|
TPL
|
Horizon Kinetics Asset Management LLC
> 10% Shareholder |
BUY
Open market or private purchase
|
Direct | 1 Added 0.0% |
$1,399
$1399.62 p/Share
|
Jan 17
2025 |
|
ACCD
|
Robert N Cavanaugh
President |
SELL
Open market or private sale
|
Direct | 186 Reduced 0.09% |
$1,275
$6.86 p/Share
|
Jan 17
2025 |
|
ACCD
|
Stephen H. Barnes
Chief Financial Officer |
SELL
Open market or private sale
|
Direct | 154 Reduced 0.07% |
$1,056
$6.86 p/Share
|
Jan 17
2025 |
|
ACCD
|
Rajeev Singh
Chief Executive Officer |
SELL
Open market or private sale
|
Direct | 309 Reduced 0.04% |
$2,119
$6.86 p/Share
|
Jan 17
2025 |
|
COSM
|
Grigorios Siokas
Chief Executive Officer |
BUY
Open market or private purchase
|
Direct | 29,158 Added 0.7% |
$25,075
$0.86 p/Share
|
Jan 17
2025 |
|
ACN
|
Mauro Macchi
Chief Executive Officer-EMEA |
SELL
Open market or private sale
|
Direct | 1,000 Reduced 16.74% |
$354,260
$354.26 p/Share
|
Jan 17
2025 |
|
ACN
|
Angela Beatty
Chief Leadership & HR Officer |
SELL
Open market or private sale
|
Direct | 961 Reduced 14.91% |
$340,780
$354.61 p/Share
|
Jan 17
2025 |
|
ACN
|
Manish Sharma
CEO-The Americas |
SELL
Open market or private sale
|
Direct | 1,557 Reduced 20.89% |
$552,112
$354.6 p/Share
|
Jan 17
2025 |
|
ACN
|
Angie Y Park
Chief Financial Officer |
SELL
Open market or private sale
|
Direct | 685 Reduced 7.32% |
$243,127
$354.93 p/Share
|
Jan 17
2025 |
|
ACN
|
Julie Spellman Sweet
Chair and CEO |
SELL
Open market or private sale
|
Direct | 2,497 Reduced 7.96% |
$886,310
$354.95 p/Share
|
Jan 17
2025 |
|
STZ
|
William T Giles
Director |
BUY
Open market or private purchase
|
Direct | 1,000 Added 40.6% |
$186,390
$186.39 p/Share
|
Jan 17
2025 |
|
BDX
|
Michael David Garrison
EVP & President, Medical |
SELL
Open market or private sale
|
Direct | 597 Reduced 9.72% |
$141,196
$236.51 p/Share
|
Jan 17
2025 |
|
SCWO
|
Yaacov Nagar |
SELL
Open market or private sale
|
Direct | 114,998 Reduced 0.31% |
$68,998
$0.6 p/Share
|
Jan 17
2025 |
|
IZTC
|
Michael Heltzen
Chief Executive Officer |
BUY
Open market or private purchase
|
Direct | 1,767 Added 31.34% |
$19,048
$10.78 p/Share
|
Jan 17
2025 |
|
MRVL
|
Mark Casper
EVP & Chief Legal Officer |
SELL
Open market or private sale
|
Direct | 7,755 Reduced 100.0% |
$954,485
$123.08 p/Share
|
Jan 17
2025 |
|
NYC
|
Nicholas S Schorsch
> 10% Shareholder |
BUY
Open market or private purchase
|
Indirect | 1,367 Added 0.0% |
$12,590
$9.21 p/Share
|
Jan 17
2025 |
|
ADAP
|
Adrian Rawcliffe
Chief Executive Officer |
SELL
Open market or private sale
|
Direct | 30,601 Reduced 40.84% |
$17,748
$0.58 p/Share
|
Jan 17
2025 |
|
ADAP
|
William C Bertrand Jr
Chief Operating Officer |
SELL
Open market or private sale
|
Direct | 5,584 Reduced 42.65% |
$3,238
$0.58 p/Share
|
Jan 17
2025 |
|
ADAP
|
John Lunger
Chief Patient Supply Officer |
SELL
Open market or private sale
|
Direct | 5,584 Reduced 42.65% |
$3,238
$0.58 p/Share
|
Jan 17
2025 |
|
ADAP
|
Elliot Norry
Chief Medical Officer |
SELL
Open market or private sale
|
Direct | 5,584 Reduced 42.65% |
$3,238
$0.58 p/Share
|
Jan 17
2025 |
|
COMP
|
Robert L. Reffkin
Chairman and CEO |
SELL
Open market or private sale
|
Direct | 42,717 Reduced 2.14% |
$294,747
$6.9 p/Share
|
Jan 17
2025 |
|
SKYH
|
Boston Omaha Corp
> 10% Shareholder |
SELL
Open market or private sale
|
Direct | 7,861 Reduced 0.07% |
$89,300
$11.36 p/Share
|
Jan 17
2025 |
|
MDGL
|
Shannon T Kelley
General Counsel |
SELL
Open market or private sale
|
Direct | 277 Reduced 3.47% |
$75,734
$273.41 p/Share
|
Jan 17
2025 |
|
MDGL
|
Rebecca Taub
Pres., R&D, and CMO |
SELL
Open market or private sale
|
Direct | 1,689 Reduced 0.37% |
$461,789
$273.41 p/Share
|
Jan 17
2025 |
|
MDGL
|
Robert E. Waltermire
Senior VP, Chief Pharma Dev. |
SELL
Open market or private sale
|
Direct | 442 Reduced 8.04% |
$120,847
$273.41 p/Share
|
Jan 17
2025 |
|
ONTF
|
Steven Vattuone
Chief Financial Officer |
SELL
Open market or private sale
|
Direct | 1,022 Reduced 0.19% |
$6,643
$6.5 p/Share
|
Jan 17
2025 |
|
TEM
|
Bradley A Keywell
> 10% Shareholder |
SELL
Open market or private sale
|
Indirect | 265,000 Reduced 0.0% |
$9,394,250
$35.45 p/Share
|
Jan 17
2025 |
|
TEAM
|
Michael Cannon Brookes
CEO, Co-Founder |
SELL
Open market or private sale
|
Indirect | 7,948 Reduced 0.0% |
$2,022,686
$254.49 p/Share
|
Jan 17
2025 |
|
TEAM
|
Scott Farquhar |
SELL
Open market or private sale
|
Indirect | 7,948 Reduced 0.0% |
$2,022,686
$254.49 p/Share
|
Jan 17
2025 |
|
TEAM
|
Anutthara Bharadwaj
President |
SELL
Open market or private sale
|
Direct | 1,520 Reduced 0.72% |
$394,972
$259.85 p/Share
|
Jan 17
2025 |
|
ULCC
|
Barry Biffle
CEO |
SELL
Open market or private sale
|
Direct | 273,000 Reduced 25.05% |
$2,304,120
$8.44 p/Share
|
Jan 17
2025 |
|
AGBAR
|
Robert E. Diamond Jr. |
SELL
Open market or private sale
|
Indirect | 120,000 Reduced 0.0% |
$295,200
$2.46 p/Share
|
Jan 17
2025 |
|
PDEX
|
Raymond E Cabillot
Director |
SELL
Open market or private sale
|
Indirect | 6,820 Reduced 0.0% |
$305,467
$44.79 p/Share
|
Jan 17
2025 |
|
LWAY
|
Ludmila Smolyansky |
SELL
Open market or private sale
|
Indirect | 12,034 Reduced 0.0% |
$271,366
$22.55 p/Share
|
Jan 17
2025 |
|
ETD
|
M Farooq Kathwari
Chairman, President & CEO |
SELL
Open market or private sale
|
Indirect | 700 Reduced 0.0% |
$20,069
$28.67 p/Share
|
Jan 17
2025 |
|
ETD
|
M Farooq Kathwari
Chairman, President & CEO |
SELL
Open market or private sale
|
Direct | 10,000 Reduced 0.6% |
$286,700
$28.67 p/Share
|
Jan 17
2025 |
|
OPK
|
Phillip Md Et Al Frost
CEO & Chairman |
BUY
Open market or private purchase
|
Indirect | 150,000 Added 0.0% |
$220,500
$1.47 p/Share
|
Jan 17
2025 |